Feb 10 (Reuters) - AstraZeneca on Thursday forecast higher 2022 sales after the drugmaker posted better-than-expected fourth-quarter profit as it gets a lift from its COVID-19 antibody treatment.
The drugmaker, however, like rival GSK , warned that its gross profit margin from coronavirus products is expected to be lower than the company average for this year, while sales are expected to decline by a low-to-mid twenties percentage.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments